Objective

Clear cell renal cell carcinoma (ccRCC) is the most prevalent kidney cancer. The genetic cause of ccRCC is associated to the mutation of the von Hippel&hypen;Lindau (VHL) gene. Absence of VHL causes the accumulation of hypoxia inducible factor (HIF) and inappropriate target gene expression. The lysyl oxidase (LOX) gene is one of the transcriptional targets of HIF. Abnormal expressions of LOX family members have been reported in various cancer including ccRCC. They have been implicated in malignant tumour progression. In this study,  new synthesized inhibitors that designed to target the LOX and LOXL2 were tested on ccRCC cells in vitro. Trypan blue and cell counting assay (CCK-8) were performed to exam the effects of these inhibitors on cell proliferation and viability. Three inhibitors have shown significant inhibition of ccRCC cell proliferation and/or reduction of cell viability (p<0.05) when compared to the negative control treatment Further investigation is required to identify the effects of these potential drugs on the bioactivities of ccRCC. These inhibitors may hold great therapeutic promise.